May, 2020 - Orphan Drug Consulting

Pharmaceutical Business Continuity Plan as a Key Component of COVID-19 Pandemic Response

“To be a proper business continuity plan, a company needs to roll it out across its entire organization, there needs to be clear roles and responsibilities for people and the plan needs to be simulated and practiced.” In response the COVID-19 pandemic, this webinar examines business continuity planning as a risk mitigation strategy. David

EU Regulatory Flexibility During COVID-19 Pandemic

In these uncertain times it can be challenging to comply with regulatory requirements while maintaining supply demands, but there has been advice published by the authorities to help. This guidance has outlined regulatory flexibility that can be applied to help pharmaceutical companies cope with the consequences of the pandemic, while ensuring a high level of

Monthly archives: May, 2020

Pharmaceutical Business Continuity Plan as a Key Component of COVID-19 Pandemic Response

EU Regulatory Flexibility During COVID-19 Pandemic

Categories

Photostream

Archives